Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and over $14 billion in the first nine months of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). This Scandinavian economic behemoth was one of the highest-valued companies in Europe at over $500 billion, which exceeds Denmark's entire gross domestic product. Ironically, Ozempic and Wegovy, like many of Novo Nordisk's other prod ...

A Minnesota jury awarded $65.5 million on Friday to a mother of three who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing cancer in the lining of her lungs.Jurors determined that plaintiff Anna Jean Houghton Carley, 37, should be compensated by Johnson & Johnson after using its baby powder throughout her childhood and later developing mesothelioma, an aggressive cancer caused primarily by exposure to the carcinogen asbestos.Johnson & Johnson said i ...

The middle class trades time for money while the wealthy build systems that generate income around the clock. This fundamental difference explains why some people work their entire lives without accumulating significant wealth, while others achieve financial independence within a decade or two.Passive income isn’t about get-rich-quick schemes. It’s about putting your capital and knowledge to work in ways that compound over time without requiring your constant attention.The five strategies below represent pr ...

US President Donald Trump announced deals with nine pharmaceutical companies on Friday, the latest in a series of pacts designed to lower drug prices for some Americans in exchange for a three-year reprieve from threatened tariffs.The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they d ...

加利福尼亚州圣地亚哥, Dec. 21, 2025 (GLOBE NEWSWIRE) -- Sapu BioScience 今日宣布在《国际分子科学杂志》上发表了一项新的同行评审研究，该研究进一步巩固了生物标志物导向的紫杉类药物治疗的科学基础，彰显了该公司在转化生长因子-β2 (TGFB2) 生物学领域的长期领导地位。 通过生物信息学方法识别乳腺癌中依赖 TGFB2 的良好预后生物标志物与不依赖 TGFB2 的不良预后生物标志物。 Qazi S，Richardson S，Potts M，Myers S，Trieu V。《国际分子科学杂志》。 2025 年 11 月 29 日；26(23):11580。 doi：10.3390/ijms262311580。 PMID：41373732; PMCID: PMC12692321。 该研究表明，TGFB2 不仅是预后标志物，更是决定患者在紫杉类药物等标准化疗中能否获益的生物学背景设定因子。 这一发现对 Sapu 的紫杉类药物项目 Sapu-001 具有直接 指导意义——该项目旨在通过精准患者筛选和优化给药方案，提高紫杉类药物治疗的疗效与耐受性。 Sapu BioSci ...

Ah, the stock market. A bastion of rational thought, predictable trends, and calm, measured reactions. Or, if you’ve been paying attention to the last few years, a chaotic pinball machine where the flippers are controlled by presidential tweets and the ball bounces wildly between “historic deals” and “massive tariffs.” Welcome back to the exhilarating, if slightly whiplash-inducing, world of the Trump economy, where policy pronouncements often serve as the opening bell for a fresh round of market gymnastics ...

事件概述 - 美国总统特朗普预计于周五宣布旨在降低处方药价格的新协议 公告定于美国东部时间下午1点在白宫举行 [1][5] - 艾伯维、百时美施贵宝、吉利德科学和默克等主要制药商预计将宣布降低部分药品价格的协议 [1][5] - 瑞士制药商诺华和罗氏预计也将参与 [5] 政策背景与公司参与情况 - 特朗普于7月向17家主要制药公司领导人致信 概述了它们应如何向美国政府针对低收入人群的医疗补助计划提供所谓的最惠国价格 并保证新药定价不高于其他高收入国家 [2][5] - 截至目前已有五家公司与政府达成控制价格的协议 它们是辉瑞、礼来、阿斯利康、诺和诺德以及德国默克集团的美国分部EMD Serono [5] - 其余12家公司为赛诺菲、再生元、默克、强生、艾伯维、安进、吉利德、勃林格殷格翰、百时美施贵宝、葛兰素史克、诺华以及罗氏的美国子公司基因泰克 [5] - 百时美施贵宝、吉利德和白宫未立即回应置评请求 艾伯维和默克拒绝置评 [5] - 诺华表示正在与特朗普政府进行讨论 并致力于寻找降低美国人成本的解决方案 罗氏表示支持特朗普降低药品成本的目标 并鼓励其他国家奖励生物制药创新 [5] 市场影响与分析 - 特朗普长期关注美国与其他富裕国家之间的药价差异 后者拥有可协商价格折扣的政府运营医疗系统 [5] - 美国政府加强价格控制的前景最初吓坏了投资者 但迄今为止宣布的交易条款缓解了许多此类担忧 [5] - 分析师指出 医疗补助计划仅占美国药品支出的约10% 并且已经享有大幅价格折扣 在某些情况下超过80% [5][6] - 辉瑞在周二宣布其2026年财务展望时表示 医疗补助折扣将在明年导致价格和利润率受到挤压 [5][6]

Medicus Pharma (NASDAQ:MDCX) CEO Dr Raza Bokhari talked with Proactive about the company completing patient enrollment in its SkinJect clinical trial. The company has now enrolled 90 patients across nine sites in the United States as part of its clinical development program for Skinject, a novel, noninvasive treatment for non-melanoma skin diseases, specifically basal cell carcinoma. Proactive: All right, welcome back inside our Proactive newsroom. And joining me now is Dr Raza Bokhari. He is the CEO of Med ...

NEW YORK, Dec. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Telix securities during the Class Period you may be entitled to compensation without payment of any out o ...

文章核心观点 - 市场焦点正转向塑造2026年股市表现的结构性力量 人工智能模型ChatGPT被用于识别具备持续盈利能力和韧性的主导行业[1] - ChatGPT识别出两个有望在2026年引领市场的行业：科技和医疗保健[2] 科技行业 - 科技行业预计仍将是2026年市场主导的主要引擎 驱动力来自人工智能在各行业的持续扩张[3] - 主要投行和策略师普遍预期人工智能将继续成为企业盈利最强大的增长催化剂 因企业持续增加对云计算、半导体和数字化转型的支出[3] - 大型金融机构预测 人工智能相关投资将成为2026年整体市场增长的关键贡献者 使科技行业保持在盈利增长的中心[4] - 基础设施需求的规模和持续性进一步增强了该行业的前景 人工智能发展需要巨大的计算能力 维持着对数据中心、网络设备、软件平台和自动化工具的大量投资[4] - 此支出周期惠及从芯片设计商到云服务提供商等广泛的科技公司 强化了人工智能驱动增长是结构性而非投机性的观点[5] - 多个科技子领域正在并行发展 包括专注于人工智能的半导体、通过订阅和企业解决方案将人工智能货币化的软件平台 以及支持日益数字化运营的云和数据基础设施[6] - 人工智能在企业与消费市场的广泛采用 使科技行业成为2026年领先的增长引擎 尽管公司层面的表现可能有所不同[6] 医疗保健行业 - 医疗保健行业被确定为2026年第二个有望领先的行业 兼具创新驱动增长和防御性特征 在经济放缓时期需求相对稳定 在高估值和持续波动的市场环境中具有吸引力[7] - 医疗保健行业正在经历技术转型 人工智能正在加速药物发现、改善诊断、实现个性化医疗并提高运营效率 这些进步正在创造超越传统人口结构驱动需求的新收入来源[8] - 近年来表现落后于大盘后 许多医疗保健股交易价格处于相对折价状态 ChatGPT强调了均值回归的预期不断增强 催化剂包括生物技术并购、新药获批以及数字健康解决方案的扩展[11] - 该行业的多元化进一步增强了其吸引力 涵盖制药与生物技术、医疗器械与诊断以及医疗保健服务 结合了创新主题与老龄化人口和长期护理需求相关的基本服务的稳定性[12]